Cargando…

Spinal muscular atrophy

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. Estimated incidence is 1 in 6,000 to 1 in 10,000 live births and carrier frequency o...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Amico, Adele, Mercuri, Eugenio, Tiziano, Francesco D, Bertini, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231874/ https://www.ncbi.nlm.nih.gov/pubmed/22047105 http://dx.doi.org/10.1186/1750-1172-6-71

Ejemplares similares

Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?
por: Pera, Maria Carmela, et al.
Publicado: (2020)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)

Growth patterns in children with spinal muscular atrophy
por: De Amicis, Ramona, et al.
Publicado: (2021)

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
por: Valsecchi, Valeria, et al.
Publicado: (2023)

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies
por: Pane, Marika, et al.
Publicado: (2023)

Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
por: Errico, Francesco, et al.
Publicado: (2022)

Body mass index in type 2 spinal muscular atrophy: a longitudinal study
por: Ferrantini, Gloria, et al.
Publicado: (2022)

Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020)

New therapies for spinal muscular atrophy: where we stand and what is next
por: Antonaci, Laura, et al.
Publicado: (2023)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy
por: Tiziano, Francesco D., et al.
Publicado: (2010)

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
por: Pane, Marika, et al.
Publicado: (2022)

Congenital Muscular Dystrophies: A Brief Review
por: Bertini, Enrico, et al.
Publicado: (2011)

SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples
por: Abiusi, Emanuela, et al.
Publicado: (2021)

Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study
por: Trucco, Federica, et al.
Publicado: (2021)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Different trajectories in upper limb and gross motor function in spinal muscular atrophy
por: Coratti, Giorgia, et al.
Publicado: (2021)

Reply to: The need for evidence‐based treatment decisions in spinal muscular atrophy type 0
por: Mercuri, Eugenio, et al.
Publicado: (2021)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

miRNAs as serum biomarkers for Duchenne muscular dystrophy
por: Cacchiarelli, Davide, et al.
Publicado: (2011)

Longitudinal natural history of type I spinal muscular atrophy: a critical review
por: Mercuri, Eugenio, et al.
Publicado: (2020)

The use of muscle biopsy in the diagnosis of undefined ataxia with cerebellar atrophy in children
por: Terracciano, Alessandra, et al.
Publicado: (2012)

Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening
por: Pane, Marika, et al.
Publicado: (2022)

25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy
por: Tiziano, Francesco Danilo, et al.
Publicado: (2020)

A Recurrent Pathogenic Variant of INPP5K Underlies Autosomal Recessive Congenital Muscular Dystrophy With Cataracts and Intellectual Disability: Evidence for a Founder Effect in Southern Italy
por: D’Amico, Adele, et al.
Publicado: (2020)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey
por: Coratti, Giorgia, et al.
Publicado: (2023)

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe
por: Kayadjanian, Nathalie, et al.
Publicado: (2013)

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
por: Kirschner, Janbernd, et al.
Publicado: (2020)

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
por: Pera, Maria C., et al.
Publicado: (2017)

Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy
por: Ahmad, Saif, et al.
Publicado: (2016)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Revisiting the role of mitochondria in spinal muscular atrophy
por: James, Rachel, et al.
Publicado: (2021)

Advances and limitations for the treatment of spinal muscular atrophy
por: Day, John W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tr6iav2tbrjiem2tembo5bq6us